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Until now ~30–40% of patients with advanced lung cancer develop bone metastases, but
as the newer therapies are extending survival, the chance of developing bone metastases
increases. Bone metastases cause skeletal-related events (SREs) such as pathologic frac-
tures, spinal cord compression, radiation therapy or surgery to bone, or hypercalcemia,
which can have debilitating consequences affecting patients’ health-related quality of life
(HR-QOL) and performance status (PS). Poor PS then prevents the patients to receive fur-
ther lines of treatments, which are available today. SREs are associated with increased
economic costs. In one clinical trial, the median time to first SRE was only 5 months. Early
detection of bone metastases can prevent SREs and avoid inappropriate implementation
of major surgery or chemoradiation therapy.With the new generation bisphosphonate zole-
dronic acid (ZA) or denosumab (anti-RANKL activity), one can reduce the number of patients
who experience SREs, decrease the annual incidence of SREs and delay the median time to
first SRE.These agents are effective even after the onset of SREs.They are well tolerated,
with manageable side effects. The biochemical markers of bone metabolism especially N-
telopeptide of type I collagen and bone specific alkaline phosphatase (BALP) can be both
prognostic and predictive markers for the patients with bone metastases from non-small
cell lung cancer (NSCLC). Anticancer activity of ZA and denosumab further supports their
use as soon as bone metastases are diagnosed in patients with NSCLC. Further trials will
inform us about the efficacy of these agents for prevention of bone metastases and even
about possible effects on visceral metastases.
Keywords: bone metastases, denosumab, zoledronic acid, NSCLC, biomarkers, skeletal-related events, effect on
pain and survival
INTRODUCTION
Approximately 30–40% of patients with lung cancer develop bone
metastases (1), which can lead to skeletal-related event (SREs) such
as pathologic fractures, spinal cord compression, radiation therapy
or surgery to bone, or hypercalcemia. These SREs can affect the
patient’s health-related quality of life (HR-QOL). Bone metastases
are the most common cause of cancer-associated pain in patients
with advanced malignancies (2). The bone pain associated with
bone metastases often requires palliative radiation therapy. Patho-
logic fracture, which may require surgery, spinal cord compression,
and hypercalcemia of malignancy (HCM) can be life-threatening.
In a large prospective trial, pathologic fractures were significantly
and negatively correlated with survival among 460 patients with
bone metastases from solid tumors, including breast, prostate, kid-
ney, and lung cancers (3). SREs not only cause increased morbidity
and deterioration of performance status (PS), but also increased
economic costs (4), thus SRE prevention will not only decrease
patient morbidity, improve HR-QOL, but will also be associated
with decreased use of health care resources. The need to focus on
bone metastases and their sequelae is heightened as the survival of
patients with non-small cell lung cancer (NSCLC) increases with
the newer therapies. In one clinical trial, median time to first SRE
in patients with NSCLC was 5 months only (5). To prevent SREs,
preserve patients’ QOL, good PS, and functional independence are
of great importance and will allow patients to receive all the lines
of therapies now available.
PATHOPHYSIOLOGY OF BONE METASTASES
The release of growth factors from the bone matrix during
osteoclast-mediated osteolysis is conducive to the development
of metastatic lesions (6). In osteolytic lesions, factors secreted
by tumor cells induce osteoclast recruitment and activation,
leading to increased osteolysis (7). Elevated osteolysis decreases
bone integrity, can cause bone pain and the release of minerals
from the bone matrix, resulting in HCM (8). Bone resorption
releases growth factors that stimulate tumor growth and increase
of osteoclast-stimulating factors (9). In contrast, tumor cells in
osteoblastic lesions secrete factors that stimulate osteoblasts, which
are responsible for the formation of new bone tissue (osteogen-
esis). Levels of osteolysis are enhanced in response to increased
osteogenesis, releasing growth factors from the bone matrix (7).
Osteoblastic lesions may also contain a strong osteolytic compo-
nent that can decrease bone integrity (9, 10). Aberrant new bone
formation in osteoblastic lesions produces new bone tissue that
is abnormal, malformed, and does not add to the overall bone
strength (9, 11).

























































Hirsh Treatment of bone metastases in lung cancer
FIGURE 1 | Zoledronic Acid reduced percentage of patients with each
SRE. Phase III trial of patients with bone metastases from NSCLC/OST
who received ZOL or placebo every 3 weeks for up to 21 months.
Approximately 50% of patients had NSCLC; ~7% of patients had SCLC.
SRE, skeletal-related event; mets, metastases; NSCLC, non-small cell
lung cancer; OST, other solid tumors; RT, radiotherapy; SCC, spinal cord
compression; HCM, hypercalcemia of malignancy. Data from Rosen
et al. (5).
EARLY DETECTION OF BONE METASTASES
The incorrect staging of patients with NSCLC can result in subop-
timal treatment decisions such as major surgery or an aggressive
chemoradiation without hope for a curative outcome.
Recently, PET scanning for accurate staging of NSCLC has
been recognized as a valuable tool by the National Comprehen-
sive Cancer Network (12). Fluorine-18 deoxyglucose (FDG)-PET
scans for the detection of bone metastases in NSCLC have been
shown to have a higher specificity compared with bone scans
(~90 versus 70%, respectively) (13, 14) and a much lower rate
of false negatives (6 versus 39%, respectively) (15). The sensitivity
of FDG-PET and bone scans for the detection of bone metastases
from NSCLC was comparable after appropriate follow-up imaging
(13, 14).
CLINICAL IMPLICATIONS OF BONE
METASTASES – BISPHOSPHONATES, ZOLEDRONIC ACID
Bisphosphonates are pyrophosphate analogs that are deposited at
sites of bone remodeling. They bind to bone mineral surfaces and
are ingested by osteoclasts wherein they inhibit osteolysis (16).
Early bisphosphonates i.e., etidronate, clodronate, demonstrated
efficacy for the treatment of HCM, but these agents are weak with
limited utility in the oncology setting (16).
The introduction of a nitrogen group to the bisphosphonate
backbone resulted (17) in increased potency and a different cel-
lular target: farnesyl diphosphonate synthase, a key enzyme in
the mevalonate pathway. These bisphosphonates inhibit protein
prenylation and RAS signaling in osteoclasts, thereby inducing
apoptosis (18). Zoledronic acid consistently achieved the great-
est antiresorptive efficacy among the bisphosphonates tested in
preclinical assays in human cancer cell lines and animal models
(19, 20).
Regulatory approval for zoledronic acid (ZA) in patients with
any solid tumors was based on results from a phase III random-
ized, placebo-controlled trial in which 773 patients with bone
metastases from solid tumors other than breast or prostate can-
cer received ZA (4 or 8 mg) or placebo via 15 min intravenous
infusion every 3 weeks for up to 21 months (5). Among the 507
patients randomized to the 4 mg ZA or placebo group of this trial,
249 had NSCLC and 36 had small cell lung cancer (SCLC).
In the overall trial population, ZA significantly reduced the
number of patients who experienced at least one SRE, includ-
ing HCM, 39 versus 48% with placebo, p= 0.039, and reduced
the proportion of patients who experienced each type of SRE
(Figure 1) (5).
Zoledronic acid also significantly decreased the annual inci-
dence of SREs, 1.74 versus 1.71 per year for placebo, p= 0.012
and significantly delayed the median time to first SRE compared
with placebo (236 versus 155 days, respectively, p= 0.009) (5). A
multiple event analysis using a robust Andersen–Gill model was
performed for the overall population. This analysis takes into
account not only the number of SREs but also the timing between
the SREs, thereby providing a sensitive comparison of the ongoing
risk of SREs between two treatment groups.
Zoledronic acid reduced the risk of SREs by 31% versus
placebo in the overall trial population (relative risk, RR= 0.693,
p= 0.003). Many patients with lung cancer are diagnosed only
after the first SRE. However, pre-existing skeletal morbidity does
not preclude the benefits of subsequent therapy with ZA. Indeed,
patients who have already experienced an SRE are at especially
high risk for subsequent events. In an exploratory analysis of
the ZA phase III trial in patients with NSCLC and other solid
tumors, patients with a history of SRE before study entry had
a 41% increased risk of experiencing an on-study SRE com-
pared with patients with no history of prior SRE (p= 0.036)
(21). In patients with a prior SRE, ZA produced a signif-
icant 31% reduction in the risk of developing an on-study
SRE compared with placebo in a robust Andersen–Gill multi-
ple event analysis, p= 0.009, and significantly reduced the skele-
tal morbidity rate, 1.96 versus 2.81 events per year for placebo,
p= 0.030 (21).
Furthermore, ZA significantly prolonged the median time to
first SRE on study by ~4 months compared with placebo in this
prior-SRE cohort (215 versus 106 days, respectively, p= 0.011).
Benefits were also seen in the subset of patients who had not
experienced a prior SRE, but without a statistical significance
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because of lack of the statistical power. This study suggests that
ZA is effective and provides benefits even after the onset of SREs.
The most commonly reported adverse events (AEs) for ZA
and placebo during the trial were bone pain including infusion
of ZA-related pain (48 and 58%, respectively), nausea (47 and
32%, respectively), and dyspnea (45 and 30%, respectively) (22).
There was no significantly lower incidence of palliative radiother-
apy to bone in the 4 mg ZA group versus placebo (23). There were
no grade 4 increases in serum creatinine in the NSCLC stratum.
Monitoring of renal function and oral health during bisphospho-
nate therapy is recommended to avoid uncommon, but potentially
serious AEs (24, 25). Because all intravenous bisphosphonates are
cleared by the kidneys, renal function, and hydration status should
be determined before each infusion to ensure renal safety. Reduced
starting dose of ZA is recommended for patients with impaired
renal function (26).
Osteonecrosis of the jaw (ONJ) has been reported as an uncom-
mon event in patients receiving bisphosphonates and is character-
ized by exposed bone in the maxillofacial area with no evidence
of healing after 6 weeks of appropriate dental care in the absence
of metastatic disease or radiation to the jaw (25). The reports
using the data obtained from retrospective analyses and reviews
of medical records databases suggest that the frequency of ONJ
in patients with malignant bone disease may be between 0.7 and
12.6% (27–29).
This wide range in ONJ frequency is likely due to variability
in preventive dental measures before and during bisphosphonate
therapy, variations in the duration of bisphosphonate treatment,
and geographic differences. Preventive dental measures and appro-
priate oral hygiene have been identified that can significantly
reduce the incidence of ONJ during bisphosphonate therapy (25,
30–32). A pilot study in patients with active ONJ lesions found that
local application of a medical ozone oil suspension led to complete
ONJ resolution (33).
ZOLEDRONIC ACID AND BIOCHEMICAL MARKERS
In a subset of patients with NSCLC or other solid tumors in the
placebo group (238 patients), urinary levels of the bone resorp-
tion marker N-telopeptide of type I collagen (NTX) and the
serum bone formation marker bone specific alkaline phosphatase
(BALP) were assessed approximately every 3 months (34). High
NTX levels (≥100 nmol/mmol creatinine) at baseline were asso-
ciated with an increased risk of first SRE (RR= 1.85, p= 0.076)
and bone disease progression (RR= 1.76, p= 0.029) compared
with patients with low NTX levels (<100 nmol/mmol creatinine,
Figure 2) (34). Moreover, compared with patients with low NTX
levels, patients with high NTX levels had a more than threefold
increased risk of death (RR= 3.03, p< 0.001) and a 5-month
reduction in median survival (3.2 versus 8.2 months for patients
with low baseline NTX levels) (34). Patients with high baseline
BALP levels (≥146 IU/L) also had statistically significant increases
in risk of disease progression (RR= 1.77, p= 0.005) and death
(RR= 1.53, p= 0.003) compared with patients with low BALP
levels (<146 IU/L) (34).
Exploratory analysis of the ZA phase III clinical trial database
(36) showed that ZA reduced mean urinary NTX levels within
3 months in patients with bone metastases from NSCLC and
FIGURE 2 | ZOL normalized NTX levels within 3 months in most
patients with elevated baseline NTX. NTX, N-telopeptide of type I
collagen; HRPC, hormone-refractory prostate cancer; NSCLC, non-small
cell lung cancer; OST, other solid tumors; BL, baseline. Data from Lipton
et al. (35).
other solid tumors who had bone marker assessment (n= 204)
(35). ZA also significantly reduced the RR of death by 35% ver-
sus placebo (RR= 0.650, p= 0.024) among patients with NSCLC
and high baseline NTX levels (NTX≥ 64 nmol/mmol creatinine,
n= 144) (37).
Differences in survival between the ZA and placebo groups did
not reach statistical significance in the normal baseline NTX sub-
set, consistent with the lower risks of SREs and death that have
been reported for that subset (34, 37).
This benefit could result from reduced osteolysis, resulting in
less release of growth factors from the bone matrix, reduced SRE
rate or possibly also from direct and indirect antitumor effects
of ZA i.e., increased apoptosis, synergism with chemotherapy,
antiangiogenesis, and stimulation of immune system.
ANTICANCER ACTIVITY OF ZOLEDRONIC ACID
There is a preclinical evidence that ZA can inhibit proliferation and
induce apoptosis in a broad range of human cancer cell lines (16,
38) ZA also exerts antitumor synergy with chemotherapy agents
in the A549 lung cancer cell line (39, 40). In murine lung can-
cer cell line, ZA inhibited the growth of these tumors and mice
treated with ZA survived significantly longer than the untreated
mice (p< 0.05) (41).
Multiple effects may contribute to the antitumor activity of
ZA that has been reported in preclinical models (42). In addi-
tion to direct antitumor effects, nitrogen-containing bisphospho-
nates appear to have immunomodulatory properties especially
with regard to γδ T cells, a subset of T cells that plays a role
in immunosurveillance for malignancies. In an in vitro model,
ZA induced maturation and upregulated co-stimulating surface
receptor expression (e.g., CD 40, CD 80, CD 83) on peripheral γδ
T cells (43). In addition, bisphosphonates have been shown to acti-
vate the cytolytic activity of γδ T cells and therefore, may enhance
the antitumor immune response (44).
There are ongoing clinical studies in patients with NSCLC eval-
uating the efficacy of ZA both for prevention of bone metastases
and for antitumor activity.
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DENOSUMAB AND ANTI-RANKL ACTIVITY
Denosumab is a fully human monoclonal antibody that binds
to and neutralizes RANKL (receptor activator of nuclear factor
kappa-B ligand) thereby inhibiting osteoclast function and pre-
venting generalized bone resorption and local bone destruction.
It is hypothesized that tumor cells in the bone lead to increased
expression of RANKL on osteoclasts and their precursors. RANKL
is an essential mediator of osteoclast function, formation, and sur-
vival (45–47). Excessive RANKL-induced osteoclast activity results
in resorption and local bone destruction with evidence of elevated
levels of bone turnover markers, leading to SREs (34, 36).
Denosumab has been studied in two phase II trials of patients
with bone metastases in advanced cancer and in one phase II
trial with myeloma (48–50). These studies demonstrated that
treatment with denosumab at doses ranging from 30 to 180 mg
administered every 4 or 12 weeks was associated with a rapid and
sustained suppression of bone turnover markers and delay of SREs
similar to that seen with i.v. bisphosphonates.
In a randomized, double-blind phase III trial of denosumab
versus ZA, in the treatment of bone metastases in patients with
advanced cancer (excluding breast and prostate cancer) or multi-
ple myeloma, 1779 patients were enrolled onto study, 890 patients
analyzed on ZA, 886 on denosumab (51). Baseline characteris-
tics were well balanced (Table 1). The primary endpoint was time
to first on-study SRE comparing denosumab with ZA for non-
inferiority. Secondary efficacy endpoints were to be evaluated only
if non-inferiority was demonstrated, and were superiority tests
comparing denosumab and ZA for time to first on-study SRE and
time to first and subsequent SRE by multiple event analysis. A sub-
sequent SRE was defined as an event occurring ≥21 days after the
previous SRE.
The median number of doses was seven for ZA and seven for
denosumab with cumulative drug exposure of 651.9 patient-years
for ZA and 675.3 patient-years for denosumab. Median time on
study was ~7 months.







Male 552 (62) 588 (66)
Age (years) 61 60
Primary tumor type
Non-small cell lung cancer 345 (39) 343 (39)
Multiple myeloma 93 (10) 86 (10)
Other 452 (51) 457 (52)
ECOG performance status of 0 or 1 728 (82) 748 (84)
Time from first bone metastasis to
randomization (months)
2 2
Previous SRE 446 (50) 440 (50)
Presence of visceral metastases 448 (50) 474 (53)
See Ref. (52).
Denosumab was non-inferior to ZA in delaying time to first on-
study SRE (HR= 0.84, p= 0.0007) representing 16% reduction in
hazard (Figure 3). The median time to first on-study SRE was
20.6 months for denosumab and 16.3 months for ZA. The test for
superiority for time to first SRE showed p= 0.06 and therefore did
not reach statistical significance. Time to first and subsequent SREs
(multiple events) analysis demonstrated a rate ratio of 0.90 for
denosumab compared with ZA, p= 0.14, which was not statisti-
cally significant. Overall survival (HR= 0.95,p= 0.43) and disease
progression (HR= 1.00, p= 1.0) were similar between treatment
groups (Figures 4 and 5).
The effect of denosumab on time to first on-study SRE relative
to ZA by tumor stratification factors resulted in an HR= 0.84 for
NSCLC, p= 0.20; 1.03 for myeloma, p= 0.89, and 0.79 for other
solid tumors, p= 0.04. An ad hoc analysis examining overall sur-
vival demonstrated an HR= 0.79 for NSCLC, 2.26 for myeloma,
and 1.08 for other solid tumors.
Patients in both arms experienced similar rates of AEs (Table 2).
Rates of serious AEs are 13.4% for ZA versus 14.6% for deno-
sumab. New primary malignancy occurred in three patients
(0.3%) receiving ZA and in five patients (0.6%) receiving deno-
sumab.
Adverse events of hypocalcemia occurred more frequently with
denosumab (10.8% denosumab, 5.8% ZA). In general, the clin-
ical consequences of hypocalcemia were not observed. Centrally
determined grade 3 and 4 decreases in albumin-adjusted calcium
values were reported in 9 patients (1%) receiving ZA and 20
patients (2.3%) receiving denosumab. IV calcium was adminis-
tered on study to 2.7% of patients receiving ZA and 5.7% receiving
denosumab.
Positive adjudicated ONJ occurred with cumulative incidence
rates in the ZA and denosumab groups of 0.6 and 0.5% at 1 year,
respectively, 0.9 and 1.1% at 2 years, and 1.3 and 1.1% at 3 years
(p= 1.0).
Adverse events associated with acute phase reactions within
the first 3 days after dose 1 occurred in 14.5% of patients receiv-
ing ZA versus 6.9% receiving denosumab. Most frequent reac-
tions were pyrexia, arthralgia, and fatigue. One hundred fifty-two
patients (17.3%) on ZA required dose adjustments to levels lower
than 4 mg and doses were withheld because of elevated serum
creatinine in 78 patients (8.9%). No dose adjustments or dose
withholding for renal function were required for denosumab.
Despite appropriate adjustments of the ZA dosing regimen for
renal function, there was an evidence of an excess of renal AEs
with ZA. Denosumab has no limitations with respect to renal
impairment as it is a monoclonal antibody and is eliminated by
intracellular catabolism in phagocytes, with no evidence of renal
effects (53, 54).
BONE TURNOVER BIOMARKERS – DENOSUMAB VERSUS
ZOLEDRONIC ACID
Patients treated with denosumab experienced a greater suppres-
sion of bone turnover markers than with ZA. Between baseline and
study week 13 levels of urinary NTX/Cr decreased by a median
of 76% for denosumab (n= 546) and 65% for ZA (n= 543),
p< 0.001 and BALP decreased by 37% for denosumab (n= 578)
and 29% for ZA (n= 581), p< 0.001.
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FIGURE 3 |Time to first on-study SRE (52).
FIGURE 4 | Overall survival (52).
EXPLORATORY ANALYSIS OF OVERALL SURVIVAL IN LUNG
CANCER
Sub-analysis of 811 patients with any lung cancer showed that
denosumab was associated with significantly improved over-
all median survival compared with ZA, with a difference of
1.2 months (KM median= 8.9 versus 7.7 months, HR= 0.80,
p= 0.01) (Figure 6) (55). Denosumab continued to show a
significant survival advantage over ZA when overall survival was
adjusted for relevant baseline covariates (age, sex, time from diag-
nosis of primary cancer to first evidence of metastasis or the first
bone metastasis, visceral metastasis, and ECOG status) and strat-
ified by the randomization stratification factors (previous SRE
and systemic anticancer therapy), HR= 0.81, p= 0.01. In patients
with visceral metastases (231 in denosumab group and 233 in
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FIGURE 5 | Overall disease progression (52).
Table 2 | Adverse events of interest.




Infectious AEs 349 (39.7) 358 (40.8)
Infectious serious AEs 118 (13.4) 128 (14.6)
Acute phase reaction (first 3 days) 127 (14.5) 61 (6.9)
Potential renal toxicity AEsa 96 (10.9) 73 (8.3)
Renal failure 25 (2.8) 20 (2.3)
Acute renal failure 16 (1.8) 11 (1.3)
Cumulative rates of ONJ* 11 (1.3) 10 (1.1)
Year 1 5 (0.6) 4 (0.5)
Year 2 8 (0.9) 10 (1.1)
New primary malignancy 3 (0.3) 5 (0.6)
aIncludes blood creatinine increased, renal failure, renal failure acute, proteinuria,
blood urea increased, renal impairment, urine output decreased, anuria, oliguria,
azotemia, hypercreatininemia, creatinine renal clearance decreased, renal failure
chronic, blood creatinine abnormal.
*p=1.0.
No neutralizing anti-denosumab antibodies were detected.
See Ref. (52).
ZA group), denosumab was also associated with improved overall
median survival with a difference of 1.2 months (KM median= 7.7
versus 6.4 months, HR= 0.79, p= 0.03). Denosumab was asso-
ciated with significantly improved survival in patients with
NSCLC with a difference of 1.5 months (KM median= 9.5 versus
8.1 months, HR= 0.78, p= 0.01) (Figure 7).
Explanation for the longer survival with the denosumab treat-
ment in these lung cancer patients includes both direct and indirect
effects on tumor cells. An indirect effect may derive from the
symbiotic relationship between tumor cells and the bone marrow
microenvironment in which both bone destruction and tumor
growth are promoted. Tumor cells secrete various factors that
stimulate production of RANKL (45). The increased expression
of RANKL in the tumor environment leads to increased forma-
tion, activation, and survival of osteoclasts and results in osteolytic
lesions (56). Osteolysis then results in the release of growth factors
derived from bone (45, 57).
These growth factors increase the production of parathy-
roid hormone-related protein or promote tumor growth directly
(45). Bone destruction increases local extracellular calcium con-
centrations, which have also been shown to promote tumor
growth and the production of parathyroid hormone-related pro-
tein (57). Denosumab may indirectly affect skeletal tumor pro-
gression by targeting osteoclasts and disrupting the interaction
between tumor cells and the bone microenvironment. RANKL
inhibition has been shown to reduce bone lesions/osteolysis,
and skeletal tumor burden in a model of NSCLC (58) and to
enhance antitumor efficacy of other therapies on skeletal tumors
(59, 60).
Another hypothesis is that denosumab may improve survival
by directly inhibiting RANKL on RANK-expressing tumor cells,
which has been demonstrated for breast cancer cells in vivo (61)
and for a number of tumor cell lines (including lung cancer cells)
in vitro (62). RANKL inhibition may have a direct antineoplastic
effect on lung cancer cells via apoptosis or anti-migration activ-
ity (63). The hypothesis of mechanism of anticancer activities,
which inhibit RANKL or RANK-expressing tumor cells has been
described in more detail in the review article of Peters and Meylan
(64). These findings warrant further prospective clinical inves-
tigations, denosumab might have anticancer effects beyond the
skeleton (65).
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FIGURE 6 | Overall survival: patients with lung cancer.
FIGURE 7 | Overall survival: patients with NSCLC.
PROMISING NEW BONE TARGETING AGENTS
Targeting bone agents in the early stage of investigation in NSCLC
are Dasatinib (i.e., anti-src activity) (66), ACE-011 (Sotatercept –
Activin TRAP) (67, 68), Cabozantinib (anti-RET agent) (69), and
Radium 223 (targeted alpha emitter) (70).
CONCLUSION
In the palliative group of patients with metastatic lung cancer, the
HR-QOL is extremely important. Preserving a good PS, which
enables these patients to receive all the available lines of treatment
for metastatic NSCLC is also desirable.

























































Hirsh Treatment of bone metastases in lung cancer
Early identification of bone metastases and management of
SREs have become crucial for maintaining QOL and containing
healthcare costs throughout the patient’s care. The identification
of risk factors for skeletal metastases in patients with NSCLC will
help us to implement early treatment to prevent or delay the onset
of debilitating SREs.
The safety profile for ZA and denosumab is similar but sub-
cutaneous administration of denosumab offers advantages over
intravenous administration with no need for renal monitoring.
Denosumab is associated with fewer acute phase reactions, but has
a higher incidence of hypocalcemia. ONJ is similar for both agents.
Thus both agents are a reasonable option for targeted bone therapy.
Future trials are needed to inform us about efficacy of these
agents for prevention of bone metastases and effects on visceral
metastases, too, thus contributing to a longer survival in patients
with metastatic NSCLC.
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